Herceptin resistance database for understanding mechanism of resistance in breast cancer patients

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Trastuzumab (Herceptin) is a frontline therapy for Her2-positive breast cancer.
• Acquired or de novo resistance limits Trastuzumab efficacy in many patients.
• Understanding resistance mechanisms is crucial for improving treatment outcomes.

Purpose of the Study:

• To develop a comprehensive database, HerceptinR, for investigating Trastuzumab resistance at the genetic level.
• To integrate diverse genomic data for breast cancer cell lines (BCCs) to elucidate resistance pathways.
• To facilitate the identification of predictive biomarkers and optimal combination therapies.

Main Methods:

• Compilation of data from approximately 2500 assays investigating Trastuzumab sensitivity with or without supplementary drugs.
• Integration of genomic information, including gene expression, mutations, and copy number variations, from various BCCs.
• Development of the HerceptinR database to store and analyze this integrated data.

Main Results:

• HerceptinR provides a centralized resource for understanding Trastuzumab resistance mechanisms.
• The database facilitates the analysis of genetic alterations associated with varying drug responses.
• Genomic data integration enables a deeper understanding of resistance at the genetic level.

Conclusions:

• HerceptinR is a valuable resource for advancing the understanding of Trastuzumab resistance in breast cancer.
• The database can aid in the design of biomarkers for patient stratification.
• HerceptinR supports the identification of effective supplementary drugs to overcome resistance.